An Antibody That Clogs Up A Key Defense Of Cancer Cells

It's always risky to pin high hopes on cancer drugs that haven't been tested in people yet. But scientists at New York's Memorial Sloan-Kettering Cancer Center are seeing startling results with a new approach. Many internal tumors manage to shrug off chemotherapy by adding more of the so-called receptors that snare an important protein called epidermal growth factor (EGF). The malignant cells that chemotherapy just damages, but doesn't kill, are thus able to grab additional EGF and quickly repair themselves.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.